アブストラクト
Japanese
| Title | 乳癌の薬物療法 最近の進歩 |
|---|---|
| Subtitle | 特集 |
| Authors | 山下啓子, 竹下卓志, 萩尾加奈子, 押野智博, 守谷結美, 李東 |
| Authors (kana) | |
| Organization | 北海道大学病院 乳腺外科 |
| Journal | 北海道外科雑誌 |
| Volume | 65 |
| Number | 2 |
| Page | 106-110 |
| Year/Month | 2020 / 12 |
| Article | 報告 |
| Publisher | 北海道外科学会 |
| Abstract | 「要旨」乳癌の治療における薬物療法の目的は生存期間の延長である. 最近, 生存率を改善する新たな分子標的薬が次々と導入され, 乳癌の治療を大きく変えている. 早期乳癌では, 周術期に用いる抗HER2薬としてペルツズマブが, また術前薬物療法で病理学的完全奏効が得られなかったHER2陽性乳癌の術後薬物療法としてトラスツズマブ エムタンシンが適応拡大された. 転移・再発乳癌では, ホルモン受容体陽性HER2陰性乳癌に内分泌療法薬と併用するCDK4/6阻害薬(パルボシクリブ, アベマシクリブ), BRCA1/BRCA2生殖細胞変異陽性HER2陰性乳癌にPARP阻害薬(オラパリブ), PD-L1陽性トリプルネガティブ乳癌にナブパクリタキセルと併用する免疫チェックポイント阻害薬(アテゾリズマブ), トラスツズマブ エムタンシン治療歴のあるHER2陽性乳癌に抗体薬物複合体(トラスツズマブ デルクステカン)が新規に導入された. |
| Practice | 臨床医学：外科系 |
| Keywords | 乳癌, 薬物療法, 分子標的薬 |
English
| Title | Recent progress in drug therapy for breast cancer |
|---|---|
| Subtitle | Topics |
| Authors | Hiroko Yamashita, Takashi Takeshita, Kanako Hagio, Tomohiro Oshino, Yumi Moriya, Dong Li |
| Authors (kana) | |
| Organization | Department of Breast Surgery, Hokkaido University Hospital |
| Journal | The HOKKAIDO JOURNAL OF SURGERY |
| Volume | 65 |
| Number | 2 |
| Page | 106-110 |
| Year/Month | 2020 / 12 |
| Article | Report |
| Publisher | Hokkaido Surgical Society |
| Abstract | [Summary] The purpose of drug therapy for breast cancer is to improve survival. Over the last few years, new anti-cancer drugs that improve survival have been introduced into daily practice. A case in point is patients with HER2-positive early breast cancer for whom a pathological complete response is not obtained by preoperative drug therapy. These patients can now be treated perioperatively with the anti-HER2 antibody, pertuzumab, and postoperatively with trastuzumab emtansine. To treat metastatic/recurrent breast cancers that are hormone receptor-positive and HER2-negative, CDK4/6 inhibitors (palbociclib and abemaciclib) are combined with endocrine agents (aromatase inhibitors or fulvestrant). Furthermore, PARP inhibitors such as olaparib are used to treat BRCA1/BRCA2 germline-mutated, HER2-negative breast cancer. For PD-L1-positive, triple-negative breast cancer, an immune checkpoint inhibitor (atezolizumab) is combined with nab-paclitaxel. Finally, an antibody-drug conjugate composed of an anti-HER2 antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor (trastuzumab deruxtecan) is used to treat HER2-positive breast cancer patients who have previously been treated with trastuzumab emtansine. |
| Practice | Clinical surgery |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med 2017;377:122-131
- 2) 日本乳癌学会編. 乳癌診療ガイドライン 薬物療法 2018年版Ver. 4. http://jbcs.gr.jp/guidline/2018/index/yakubutu/
- 3) Wuerstlein R, Harbeck N. Neoadjuvant Therapy for HER2-positive Breast Cancer. Rev Recent Clin Trials 2017;12:81-92
- 4) von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2019;380:617-628
- 5) Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 2016;375:1925-1936
残りの6件を表示する
- 6) Goetz MP, et al. MONARCH:Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 2017;35:3638-46
- 7) Sledge GW Jr, Toi M, Neven P, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2:A Randomized Clinical Trial. JAMA Oncol 2019;6:116-124
- 8) Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl I Med 2017;377:523-533
- 9) Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 2018;379:2108-2121
- 10) 日本内分泌学会編. 免疫チェックポイント阻害薬による内分泌障害の診療ガイドライン. 日本内分泌学会雑誌 2018;94:1-11 https://doi.org/10.1507/endocrine.94.S.November_1
- 11) Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med 2020;382:610-621
